This case study provides a detailed overview of how Solnul™ established their product as a scientifically supported ingredient in the growing market after collaborating with Nutrasource.

By demonstrating a prebiotic effect at a dose of 3.5g, Solnul™ has become the first low dose RS2.

Download now to learn more.


"Solnul™ is a Canadian based nutritional success story with international aspirations. The Nutrasource/GRAS Associates team was delighted to be selected by Solnul™ as its commercialization partner for clinical and regulatory strategy, support and execution. Our team thrives when given the opportunity to be integrated on our client’s behalf from concept to claim, and Solnul™ provided this unique chance to truly work together synergistically between sponsor and provider, to each stakeholder’s success!"

William Rowe, President and CEO